NCT02655757View on ClinicalTrials.gov

Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

PHASE4CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 2, 2017

Study Completion Date

March 10, 2017

Conditions

AtherosclerosisType 2 Diabetes Mellitus

Interventions

DRUG

Sitagliptin

5 mg, 1 tablet per day for 12 months

DRUG

Placebo

Placebo,1 tablet per day for 12 months

Trial Locations (1)

100853

The General Hospital of PLA, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Li Bo

OTHER